Allarity Therapeutics posted a Q2 net loss of USD 3.41 million, widening from USD 2.32 million a year earlier; loss per share rose to USD 0.21.
Operating loss narrowed to USD 2.67 million from USD 4.13 million, as R&D fell 42% to USD 1.35 million and G&A dropped 26.82% to USD 1.33 million.
Cash and restricted cash climbed to USD 26.9 million at June 30, up from USD 14.7 million a year earlier; operating cash outflow was USD 2.6 million.
Clinical and manufacturing updates
Completed a Phase 3-ready stenoparib API manufacturing campaign in July, with all payments booked as prepaid expenses and no additional cash outlays expected.
The USPTO granted a U.S. patent covering the stenoparib DRP companion diagnostic through April 2042; CLIA certification was secured for its in-house DRP testing lab.
ALLR•
